Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: Analysis of two practice-based chart reviews.
James E. Signorovitch
Employment or Leadership Position - Analysis Group
Consultant or Advisory Role - Novartis
Research Funding - I am an employee of Analysis Group, Inc, which has received consulting fees from Novartis
Nicholas J. Vogelzang
Employment or Leadership Position - US Oncology
Consultant or Advisory Role - AVEO; Bayer; GlaxoSmithKline; Novartis; Pfizer
Research Funding - Bayer; PAREXEL International
Sumanta Kumar Pal
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Peggy L. Lin
Employment or Leadership Position - Analysis Group
Consultant or Advisory Role - Novartis
Research Funding - I am an employee of Analysis Group, Inc, which has received consulting fees from Novartis
Daniel J. George
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Michael K.K. Wong
Consultant or Advisory Role - Bristol-Myers Squibb; Merck; Novartis; Pfizer
Zhimei Liu
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Xufang Wang
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Kenneth W. Culver
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Jeffrey A. Scott
Employment or Leadership Position - Cardinal Health
Stock Ownership - Cardinal Health
Eric Jonasch
Consultant or Advisory Role - Novartis
Research Funding - Novartis